Australian Clinical Labs Limited (ASX:ACL)

Market Cap	597.18M
Revenue (ttm)	728.27M
Net Income (ttm)	30.67M
Shares Out	195.80M
EPS (ttm)	0.15
PE Ratio	19.86
Forward PE	15.90
Dividend	0.12 (3.95%)
Ex-Dividend Date	Mar 27, 2025

Volume	1,094,945
Average Volume	777,042
Open	3.050
Previous Close	3.050
Day's Range	2.985 - 3.135
52-Week Range	2.140 - 3.855
Beta	1.13
RSI	53.43
Earnings Date	Aug 26, 2025

About Australian Clinical Labs

Australian Clinical Labs Limited provides pathology diagnostic services in Australia. The company offers range of services, which include routine pathology test, advanced molecular genetics testing, harmony NIPT and first trimester screening, genetic carrier screening, chemical pathology, histopathology, and cytopathology; hematology, allergy, and immunology; serology and microbiology; and infectious molecular testing, cardiac testing services, functional pathology, veterinary pathology, and commercial drug and alcohol testing services. It offe...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2020
• Employees: 4,900
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: ACL

Financial Performance

In 2024, Australian Clinical Labs's revenue was 696.37 million, a decrease of -0.10% compared to the previous year's 697.07 million. Earnings were 23.93 million, a decrease of -33.33%.